TGFB1 and neoplasm: Having demonstrated highly effective anti-tumor function of the armored BCMA CAR T cells in the xenograft models with or without overexpression of active TGF-β in vivo, we proceeded to create an even more challenging set of conditions for the armored CAR T cells.